samedan logo
 
 
 
spacer
home > ebr > summer 2019 > fighting the global threat
PUBLICATIONS
European Biopharmaceutical Review

Fighting the Global Threat

The discovery of penicillin by Alexander Fleming in 1928 revolutionised medicine. This antibiotic soon became one of the most widely used in treating common bacterial infections, as well as pneumonia, tuberculosis, syphilis, and more (1). However, the Nobel Prize winner also predicted how an irresponsible use of penicillin could lead to the development of resistant bacteria, resulting in losing the antibiotic efficacy and death caused by a lack of alternative treatments. His concern has become a real-life scenario, affecting the medical sector and animal husbandry on a global scale.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Adrian Fellows has been involved in R&D − particularly in the fields of disinfection and infection control − since 1972. He has filed numerous successful patents in these areas and others, including thermal devices and chemical specialities. Adrian filed the first patent applications for disinfectant wipes in the early 1970s, led a multinational team in an EU framework R&D program, and was a visiting research fellow at Huddersfield University, UK. Since 2005, he has been R&D director for Gama Healthcare, which has become a leading presence in global infection control. More recently, Adrian has been involved in leading collaborative projects in developing novel means to combat AMR.
spacer
Adrian Fellows
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Cerba Research and ACT Genomics Announce Strategic Joint Venture CerbACT Asia

This expansion of the precision medicine offering includes central labs, flow cytometry, histopathology, and translational science laboratory services. Deep scientific expertise from both sides of this strategic alliance will support new growth areas for biotech and pharma clients globally and drive better patient outcomes across all phases of clinical trials.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: Summary of Year 2013

Synergy Research Group

Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement